Condition: Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma (HNSCC) · Head & Neck Cancer · Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
This is a randomized controlled, phase II clinical study designed to explore the efficacy and safety of nimotuzumab combined with immunotherapy and chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The primary endpoint of the study is the 2-year event-free survival (EFS) rate. Enrollment is expected to be completed within 2 years; all patients will be followed up for at least 2 years after the last patient is enrolled.
This description comes directly from the study's public registry record.
xin wei chen · 86+18616017916 · xinwei.chen@shgh.com
Always discuss trial participation with your own doctor first.
| Shanghai First People's Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07601737